

CENTOGENE N.V., Am Strande 7, 18055 Rostock, Germany

U.S. Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
United States

May 15, 2023

Re: Notice of disclosure filed in Exchange Act Annual Report under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Exchange Act

Ladies and Gentlemen,

Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 and Section 13(r) of the Securities Exchange Act of 1934, as amended, notice is hereby provided that Centogene N.V. made disclosure pursuant to those provisions in its Annual Report on Form 20-F for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission on May 15, 2023. The disclosure can be found under the heading “Miscellaneous— Disclosure under Iran Threat Reduction and Syria Human Rights Act of 2012 (ITRA)” in the Annual Report on Form 20-F.

Respectfully submitted,

/s/ Kim Stratton

Kim Stratton
Chief Executive Officer
Centogene N.V.

CENTOGENE N.V.
Am Strande 7

18055 Rostock, Germany

Tel: +49 (0)381 80 113 - 400
Fax: +49 (0)381 80 113 - 401
Email: info@centogene.com
www.centogene.com

Management Board:
Kim Stratton (CEO)

Miguel Coego Rios (CFO)

Prof. Peter Bauer M.D. (CMGO)

Supervisory Board:
Peer Schatz (Chairman)

Statutory seat:

Amsterdam, registered with the Kamer van Koophandel (Netherlands) under 72822872

Bank account details:

Bank: Commerzbank AG
IBAN: DE60130400000108866500
BIC: COBADEFFXXX
